Bioforce Nanosciences Holdings, Inc. · OTC:BFNH
Bioforce Nanosciences — Investor Presentation (March 2007)
27 slides from Bioforce Nanosciences's investor presentation, Mar 9, 2007
Slide 1: BioForce Nanosciences
OFORCE NANOSCIENCES BFNH March 2007 BIOFORCE www.bioforcenano.com Practical Nanotechnology™ :NANOSCIENCES
Slide 2: Disclaimer
Disclaimer Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 The written and verbal versions of this presentation contain forward-looking statements. These statements may address projections of our future financial performance, product and operation developments, accep
Slide 3: Company Overview
i Company Overview A nanotechnology company Focused on life sciences First product in this area: Nano eNabler™ system = Invented to solve problem of creating biotests small enough for analysis by Atomic Force Microscopy (AFM) = A “printer” used to merge biological materials (e.g. active proteins, vi
Slide 4: Key Facts
Key Facts Symbol BFNH “Corporate Headquarters ~~ ~ ~ ~~ — ~~ ~ Ames, IA “Stock Price (2/27/07) || 52-Week Range a $3.25 || $1.60 - $5.75 “Shares Outstanding (2/27/07) _ a —_ 24,099,950 “Market Capitalization (2/27/07) stst—CS~S — ~~ $78,300,000 “Volume (daily avg Nov ’06 — Feb 07) 3,688 “Cash (12/31
Slide 5: Capitalization Table
Capitalization Table (as of 2/27/07) eae Strike Price Fully Diluted Equity (100,000,000 authorized shares) Common Stock 24,099,950 24,099,950 Options $0.40 - $0.99 16,035 Options $1.00 - $1.99 1,469,633 Options $2.00 - $2.99 1,202,832 Options $3.00 - $3.99 20,000 Options $4.00 - $4.99 100,000 Warran
Slide 6: Management
i Management « Eric Henderson, Ph.D., Founder and CEO « 26 years molecular biology, 16 years nanotechnology " 94 peer reviewed scientific publications « $6M grant funds raised for BioForce " 8U.S. patents awarded « Kerry Frey, COO » 30 years mgmt/ops experience in medical device, pharmaceutical and
Slide 7: Board of Directors & Advisors
i Board of Directors & Advisors = Board of Directors « Eric Henderson " Kerry Frey « Larry Gold, Ph.D., CEO of SomaLogic, Inc. « Jean-Jacques Sunier, Consultant to Societe Generale’s Alternative Investments « Scientific Advisory Board « Virgil Elings, Ph.D., founder Digital Instruments (now Veeco) #
Slide 8: Company History
i Company History « Initial sales and brand recognition with early products (since 1994) « Conception to production of Nano eNabler ™ system (1999 — 2006) « Raise grant ($6M) and investor ($10M) capital (1999-2006) = Reverse merger into public shell (Feb. 2006) « First 20 Nano eNabler ™ system place
Slide 9: Product/Service Description
i Product/Service Description What we do: » Develop and commercialize nanotech tools and solutions for the life sciences What we provide to customers: « Tools opening the door for nanotech in the life sciences BioForce’s uniqueness: = Commercial products in the market » Focused strategy in the life
Slide 10: System
i Nano eNabler ™ System A unique device for precisely dispensing liquids in volumes equal to one millionth, billionth of a drop of blood Prints bioactive compounds Able to create ultraminiaturized biochips used in surface patterning of cells, molecules and particles US Patent No. 7,008,769 and paten
Slide 11: SPT Surface Patterning Tools
i SPT ™ Surface Patterning Tools Supporting Substrate Cantilever Reservoir Microchannel 4 Opening Gap "The “ink cartridges” for the Nano eNabler™ system "Formatted in many configurations to enhance their utility (e.g., build biochips, modify surfaces) "Patents pending 14 BIOFORCE www.bioforcenano.co
Slide 12: Merging Bio and Non-Bio Materials
i Merging Bio and Non-Bio Materials = Materials « Surfaces # Organic = Glass = Proteins = Silanes = Oligonucleotides « Silicon » Large DNA molecules Gold = Viruses ° ; 1. Inorganic » Alkanethiol SAMs = Quantum dots = Poly-I-lysine = Colloids = Polymers » Nanoparticles = Hydrogel =» Etchants » PDM =»
Slide 13: Life Science Focus
i Life Science Focus Nanotechnology Life Sciences 13 BIOFORCE www.bioforcenano.com Practical Nanotechnology™ : NANOSCIENCES
Slide 14: BioForce Positioning Strategy
i BioForce Positioning Strategy | Nano eNabler™! Perpetual Cycle of Opportunity Internal External *ViriChip ™ platform *Biosensors “FAST ™ *Cancer Cell Biology *Chip-On-A-Tip ™ *Stem Cell Biology Many Others eMany Others 14 B OFORCE www.bioforcenano.com Practical Nanotechnology" == = :N4NOSSIENCES
Slide 15: Potential Impact
‘Nano eNabler ™ Potential Impact : Areas (Life Sciences) Stem Cell Biology Cancer Biology Drug Discovery Diagnostics ¢ Point of care (e.g., home “whole health” tests with protein biomarkers) ¢ Microsamples (e.g., forensic and neonatal samples) ¢ Minimally invasive (e.g., just a few cells rather than
Slide 16: Applications Opportunities
i Applications Opportunities In-house R&D & placement partner programs capture additional value in key areas such as biomedicine, diagnostics and drug discovery. Examples include: ViriChip ™ platform N Nondestructive detection and identification < of whole virus (US Pat. No. 6,897,015) FAST ™ (Force
Slide 17: Pilot Sales Program
i Pilot Sales Program Samples of Nano eNabler ™ system placements and sales: Boston University - placement Russian Acad. Biomed. Sci. - sale Cornell University - placement UC Irvine - placement Georgia Tech University - UC San Francisco - placement placement Harvard Medical School - sale University
Slide 18: Case Study I - Cancer Cell Biology
i Case Study I - Cancer Cell Biology = Research Institute = Sales placement = Needed flexible, “on-the-fly” method to print biomolecules in sizes smaller than a single cell for cancer cell biology studies = Rapid printing of virtually any pattern in desired size range = Results = Allowed new discove
Slide 19: Case Study II - Bionanosensors
i Case Study IT - Bionanosensors = Research Institute — sale to Harvard Medical School = Needed flexible method for biomodification of silicon nanosensors. = Nano eNabler ™ system solved this problem by direct printing of femtoliter volumes of biomolecules on nanosensors = Results =» Overcame formid
Slide 20: Case Study III - Smart Bandages
i Case Study III - Smart Bandages = Research Institute = Placement =" Needed to build complex capabilities into bandages that treat and analyze as well as protect wounds = Results — Many tests in a single bandage Image courtesy of Lisa De Louise, Univ. of Rochester Medical Center "The Nano eNabler c
Slide 21: Target Market
i Target Market = Segments = Industry " Scientists and researchers =" Government agencies " Size = $1B Nano eNabler ™ system market size based upon AFM market trends (8,000+ AFMs sold) « Growth « Annual sales can double in each of the next 5 to 10 years # 5,000 Nano eNabler ™ system sales x $147,000
Slide 22: Competition
Competition Product Speed Reduced Reliability | Multiplexing | 1 to 20 pm Biological Features Clogging Compatibility Nano eNabler ™ Xx x X xX Xx X system Micro-contact Xx x - - xX x printing Nanopipettes - - - - xX Xx AFM - xX x : x - nanolithography Ink-jet printing Xx - X xX - X 23 BIOFORCE 2 NANO
Slide 23: Manufacturing / R&D
i Manufacturing / R&D Component specs by BioForce and supplied by third party vendors Product assembled by BioForce in Ames, IA Quality control by BioForce Current production capacity = 150 Nano eNabler ™ systems per year 150 x $147,000 = $22M annual revenue capacity Production can scale as needed 2
Slide 24: Sales & Distribution
i Sales & Distribution " « Sales Model # Direct in U.S « Distributors internationally = Pricing: Nano eNabler ™ system list price = $147,000 « Sales cycle = 6 — 18 months « Sales pipeline = 4,000 contacts in database « Established prestigious thought leaders (reference sites) =» Sales Growth " Exist
Slide 25: Sales & Distribution - Strategy
i Sales & Distribution - Strategy = 2007 « Convert 20 placed but not yet sold Nano eNabler ™ systems = Place additional systems in key locations «= Some direct (non-placement) sales = Materials inventory sufficient to build additional 20 units = 2008 « Place/sell 40 Nano eNabler ™ systems = Break-ev
Slide 26: Growth Strategy
i Growth Strategy * Organic = surface patterning = Acquisition/licensing of surface patterning companies and technology = In-house discoveries made possible with the Nano eNabler™, such as ViriChip™ platform « Collaboration with Nano eNabler ™ system users to pursue commercialization of their discov
Slide 27: Investment Summary
i Investment Summary = BioForce provides the nanotech investor with a company with real products and with years of nanotech experience « BioForce’s people have a background in science, business, operations, and start-up companies = Our process is to create sales through placements with industry lead
BioForce Nanosciences Holdings — Investor Presentation (March 2007) on 6ix